A double effect molecular switch leads to a novel potent negative allosteric modulator of metabotropic glutamate receptor 5

被引:10
|
作者
Gomez-Santacana, X. [1 ,2 ,3 ,4 ]
Rovira, X. [2 ,3 ,5 ,6 ]
Dalton, J. A. [2 ,3 ]
Goudet, C. [5 ,6 ]
Pin, J. P. [5 ,6 ]
Gorostiza, P. [4 ,7 ,8 ]
Giraldo, J. [2 ,3 ]
Llebaria, A. [1 ]
机构
[1] Inst Adv Chem Catalonia IQAC CSIC, Med Chem Lab, Barcelona 08034, Spain
[2] Univ Autonoma Barcelona, Inst Neurociencies, Lab Mol Neuropharmacol & Bioinformat, Bellaterra 08193, Spain
[3] Univ Autonoma Barcelona, Unitat Bioestadist, Bellaterra 08193, Spain
[4] Inst Bioengn Catalonia IBEC, Barcelona 08028, Spain
[5] Univ Montpellier, UMR 5203, CNRS, Inst Genom Fonct, F-34000 Montpellier, France
[6] INSERM, U661, F-34000 Montpellier, France
[7] Network Biomed Res Ctr Bioengn Biomat & Nanomed C, Barcelona, Spain
[8] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain
关键词
GROUP-III; RAT; ACTIVATION; DISCOVERY; EFFICACY; PROGRESS; LIGANDS; SERIES;
D O I
10.1039/c4md00208c
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Compounds that modulate the function of G-protein-coupled receptors (GPCRs) by binding to their allosteric sites are of potential interest for the treatment of multiple CNS and non-CNS disorders. Allosteric ligands can act either as positive (PAM), negative (NAM), or silent (SAM) receptor modulators and have numerous advantages over classic orthosteric compounds, including improved GPCR-subtype selectivity: the capacity to adapt to physiological conditions; and better safety profiles. Despite these benefits, allosteric modulators are difficult to design and optimize and are often prone to "molecular switching": a structural phenomenon by which very subtle chemical variations in the ligand result in unexpected changes in selectivity profiles or pharmacology, changing PAMs to NAMs or vice versa. Here, we report the discovery of a nanomolar and subtype selective NAM of metabotropic glutamate receptor 5 (mGlu(5)) through a targeted "double effect molecular switch" of a potent mGlu(4) PAM, and suggests a promising approach towards the discovery of novel mGluR allosteric modulators.
引用
收藏
页码:1548 / 1554
页数:7
相关论文
共 50 条
  • [41] Analysis of positive and negative allosteric modulation in metabotropic glutamate receptors 4 and 5 with a dual ligand
    Dalton, James A. R.
    Pin, Jean-Philippe
    Giraldo, Jesus
    SCIENTIFIC REPORTS, 2017, 7
  • [42] Development of Clickable Photoaffinity Ligands for Metabotropic Glutamate Receptor 2 Based on Two Positive Allosteric Modulator Chemotypes
    Hellyer, Shane D.
    Aggarwal, Shaili
    Chen, Amy N. Y.
    Leach, Katie
    Lapinsky, David J.
    Gregory, Karen J.
    ACS CHEMICAL NEUROSCIENCE, 2020, 11 (11): : 1597 - 1609
  • [43] Synthesis, Evaluation, and Radio labeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging
    Andres, Jose-Ignacio
    Alcazar, Jesus
    Maria Cid, Jose
    De Angelis, Meri
    Iturrino, Laura
    Langlois, Xavier
    Lavreysen, Hilde
    Trabanco, Andres A.
    Celen, Sofie
    Bormans, Guy
    JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (20) : 8685 - 8699
  • [44] Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu5)
    Stauffer, Shaun R.
    ACS CHEMICAL NEUROSCIENCE, 2011, 2 (08): : 450 - 470
  • [45] Tetrahydronaphthyridine and Dihydronaphthyridinone Ethers As Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 5 (mGlu5)
    Turlington, Mark
    Malosh, Chrysa
    Jacobs, Jon
    Manka, Jason T.
    Noetzel, Meredith J.
    Vinson, Paige N.
    Jadhav, Satyawan
    Herman, Elizabeth J.
    Lavreysen, Hilde
    Mackie, Claire
    Bartolome-Nebreda, Jose M.
    Conde-Ceide, Susana
    Luz Martin-Martin, M.
    Min Tong, Han
    Lopez, Silvia
    MacDonald, Gregor J.
    Steckler, Thomas
    Daniels, J. Scott
    Weaver, C. David
    Niswender, Colleen M.
    Jones, Carrie K.
    Conn, P. Jeffrey
    Lindsley, Craig W.
    Stauffer, Shaun R.
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (13) : 5620 - 5637
  • [46] Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics
    Walker, Adam G.
    Conn, P. Jeffrey
    CURRENT OPINION IN PHARMACOLOGY, 2015, 20 : 40 - 45
  • [47] Identification of monellin as the first naturally derived proteinaceous allosteric agonist of metabotropic glutamate receptor 5
    Chen, Amy N. Y.
    Hellyer, Shane D.
    Trinh, Phuc N. H.
    Leach, Katie
    Gregory, Karen J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 126 : 104 - 115
  • [48] Metabotropic glutamate receptor 5 (mGlu5)-positive allosteric modulators differentially induce or potentiate desensitization of mGlu5 signaling in recombinant cells and neurons
    Hellyer, Shane D.
    Albold, Sabine
    Sengmany, Kathy
    Singh, Junaid
    Leach, Katie
    Gregory, Karen J.
    JOURNAL OF NEUROCHEMISTRY, 2019, 151 (03) : 301 - 315
  • [49] Synergy between L-DOPA and a novel positive allosteric modulator of metabotropic glutamate receptor 4: Implications for Parkinson's disease treatment and dyskinesia
    Bennouar, Khaled-Ezaheir
    Uberti, Michelle A.
    Melon, Christophe
    Bacolod, Maria D.
    Jimenez, Hermogenes N.
    Cajina, Manuel
    Goff, Lydia Kerkerian-Le
    Doller, Dario
    Gubellini, Paolo
    NEUROPHARMACOLOGY, 2013, 66 : 158 - 169
  • [50] Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers
    Niswender, Colleen M.
    Jones, Carrie K.
    Lin, Xin
    Bubser, Michael
    Gray, Analisa Thompson
    Blobaum, Anna L.
    Engers, Darren W.
    Rodriguez, Alice L.
    Loch, Matthew T.
    Daniels, J. Scott
    Lindsley, Craig W.
    Hopkins, Corey R.
    Javitch, Jonathan A.
    Conn, P. Jeffrey
    ACS CHEMICAL NEUROSCIENCE, 2016, 7 (09): : 1201 - 1211